Eli Lilly – Foundayo before EU approval: New opportunities in the global USD 114 billion weight loss boom
Reading Time: 3 minutes
The EMA recommends Foundayo for obesity and type 2 diabetes. A EU launch is still possible in 2026. Retatrutide achieves up to 28.3% weight loss. EloraTZP and cancer therapies complement the pipeline. Mounjaro and Zepbound drive growth. The ESMO Congress and quarterly results are upcoming. Eli Lilly (LLY) achieved around 58% of US prescriptions for branded weight loss medications with Zepbound by mid-2026. Goldman Sachs sees the global market reaching USD 114 billion by 2030, with 40% from tablets. The EMA recommendation for Foundayo now...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
